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Systemic sclerosis- (SSc-) related vasculopathy, as manifested by Raynaud’s Phenomenon (RP) and digital ulcers (DUs), is
associated with signiﬁcant impairment of the quality of life and morbidity. The current vasoactive approach for SSc-RP, although
employing vasodilators, is entirely oﬀ-label. PDE-5 inhibitors improve peripheral circulation, are well tolerated, and are widely
used for various forms of constrictive vasculopathies. This class of medications has become one of the ﬁrst lines of treatment
of SSc-RP and SSc-DUs among rheumatologists that routinely treat SSc patients. Due to the lack of robust randomized clinical
trials of PDE-5 inhibitors in SSc-RP/DUs, the PDE-5 inhibitors have not been FDA approved for these particular indications,
which constitutes a signiﬁcant barrier to prescribing this category of drugs. This paper reviews the current state of evidence-based
knowledge in SSc-related vasculopathy and the use of PDE-5 inhibitors.
1.Introduction
Phosphodiesterases (PDEs) are isoenzymes that control
the level of intracellular cyclic guanosine monophosphate
(cGMP) and cyclic adenosine monophosphate (cAMP) by
hydrolyzing them [1]. The human genome encodes 21 PDE
genes which are classiﬁed in 11 families. PDE isoenzyme 5
(PDE-5) selectively breaks down the cGMP, a critical smooth
muscle tone regulator. Nitric oxide (NO), produced by nitric
oxide synthase, signals the conversion of GMP into cGMP
which accumulates inside the cell. Inhibition of the PDE-
5 enzyme increases the available intracellular cGMP which
leads to vasodilatation. Aside from corpus cavernosum,
PDE-5 is found on a variety of tissues, including platelets,
lungs, muscle, brain, retina, thymus, heart, liver, esophagus,
stomach, pancreas, small intestine [1], arterial and venous
vasculature [2], and endothelial cells [3].
Sildenaﬁl, vardenaﬁl, and tadalaﬁl are the three com-
mercially available PDE-5 inhibitors (PDE-5Is). All three
P D E - 5 I sa r ea v a i l a b l ei no r a lf o r m u l a t i o n ,a r er a p i d l y
absorbedfromthegastrointestinaltract,andaremetabolized
by hepatic enzymes via cytochrome P450 [4]. Sildenaﬁl
and vardenaﬁl have similar molecular structures, while the
tadalaﬁl molecule is diﬀerent, the diﬀerence being reﬂected
in the pharmacokinetic properties (Figure 1)[ 4]. Tadalaﬁl is
not aﬀected by food ingestion and has a terminal half-life
of 17.5 hours as opposed to sildenaﬁl and vardenaﬁl which
are aﬀected by fatty food intake and both have a half-life of
approximately 4 hours [4].
The primary Food and Drug Administration- (FDA-)
approved indication for the PDE-5Is is erectile dysfunction.
In recent years, sildenaﬁl (2005) [5] and tadalaﬁl (2009)
[6] have also been approved for use in pulmonary arterial
hypertension. Vardenaﬁl was recently shown to improve
hemodynamic parameters in patients with pulmonary arte-
rial hypertension in a randomized trial of 66 patients [7].
Raynaud’s Phenomenon (RP) is an exaggerated vasocon-
strictive response to cold and stress and is the presenting
symptom in the majority of patients with systemic sclero-
sis (SSc) [8]. An important clinical manifestation of the
scleroderma-relatedvasculopathyistheischemicdigitalulcer
(DU) which is associated with signiﬁcant morbidity [9]. Use
of PDE-5Is in SSc-related RP and DU makes pathophysio-
logic sense and has been explored in randomized fashion.
2.ClinicalTrials
As with penicillin or TNF-α blockers, the PDE-5Is history
is interesting. The initial intent was to develop PDE-
5Is as a new anti-ischemic therapy, but the early cardiac2 International Journal of Rheumatology
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Figure 1: Chemical structures of the three available PDE-5Is [4].
trials failed to excite any interest. The “adverse” eﬀect on
penile erections led to revolutionary development of erectile
dysfunction awareness and therapies [10]. Sildenaﬁl citrate
(Viagra) was approved by the FDA in 1998. Another PDE-5I,
vardenaﬁl (Levitra), came to market in September of 2003,
followed shortly by the “weekend” drug, tadalaﬁl (Cialis), in
November of 2003. Each of these individual drugs’ use in
SSc-RP and DU will be reviewed below.
2.1. Sildenaﬁl. The popular “blue pill” for erectile dysfun-
ction has been used oﬀ-label by rheumatologists for
symptomatic improvement of secondary RP and SSc-DUs.
A retrospective chart review of 10SSc patients at a single
center brieﬂy described the response to sildenaﬁl dosed from
12.5mg to 100mg daily [11]. As the letter to the editor
reports in 2005, “eight of the ten patients [···]h a da
response within few weeks, with signiﬁcant reduction in the
frequency and severity of RP. Of the eight patients who had
digital ulcers [···] six experienced complete healing of the
ulcers.” No other details were provided regarding the speciﬁc
measures used to quantify the RP improvement [11].
The physiological beneﬁt of sildenaﬁl citrate in patients
with SSc-RP was assessed in a group of 5 patients and
published as a letter to the editor in 2006 [12]. In this small
study,theobjectivemeasureoftheskintemperatureresponse
tomildcoldchallengeafterasingledoseof50mgofsildenaﬁl
citrate was conducted by thermography (thermal images
of the hands were collected every minute for 15 minutes
after the cold challenge to enable an area under the curve)
and by percentage recovery to mean baseline temperature
postcold challenge. Although this letter reported that 3 out
of the 5 patients had clear and signiﬁcant improvement
in digital temperature responses to mild cold challenge,
no other details were provided [12]. Based on this limited
information, sildenaﬁl citrate seems to be well tolerated in
patients with SSc-RP.
A randomized double-blind cross-over trial of single
dose of 50mg sildenaﬁl or α-tocopherol (100mg) was
reported in abstract form in 15 patients with RP [13].
The outcome measures reported were 75% improvement
in forearm blood ﬂow (as measured by near-infrared time-
resolved spectroscopy) and 32% increase in serum cGMP
concentration (P<0.01) in the sildenaﬁl group. Details
about how many patients had SSc-RP are not available. The
study reported no adverse events, aside from a mild decrease
in the systolic and diastolic blood pressure (P<0.05) in
the patients exposed to sildenaﬁl [13]. The only published
trial that evaluated eﬃcacy of sildenaﬁl in RP is a double-
blinded, placebo-controlled, ﬁxed-dose, cross-over study of
50mg sildenaﬁl twice daily for 4 weeks versus placebo [14].
Most subjects had secondary RP (16/18), and 6 of the
patients with secondary RP had DUs. Primary outcome
variables included RP frequency and duration as assessed
by diary cards, Raynaud’s Condition Score (RCS), capillary
ﬂow velocity by laser Doppler anemometry, and healing
of the DUs. At the end of the study, there was signiﬁcant
improvement in the frequency (35 versus 52, P = 0.0064)
and duration (581 versus 1046 minutes, P = 0.0038) of RP
attacks and in the RCS (2.2 versus 3.0, P = 0.0386). After
4 weeks of active therapy with sildenaﬁl, 2 of the 6 subjects
with DUs completely healed their ulcers, while the rest of the
subjects noted visible healing. The mean capillary blood ﬂow
velocity increased by more than 400% (from 0.13 to 0.53,
P = 0.0004) during the sildenaﬁl treatment [14]. Despite
its small size, this trial conﬁdently shows improvement in
the peripheral circulation after exposure to sildenaﬁl and
improvement of traditional measures of RP.
Aside from case reports, the eﬀect of sildenaﬁl on SSc-
DUs was not systematically studied. In 2010, Brueckner et
al. reported the results of a pilot open-label study of the
eﬀects of maximum tolerated sildenaﬁl in SSc-DUs [15].International Journal of Rheumatology 3
Sixteen patients were treated with a mean sildenaﬁl dose of
114mg/day for a mean duration of 5.2 months. There was
signiﬁcant improvement (P<0.001) in the number of DUs
from baseline (mean of 3.1/patient) to the end of sildenaﬁl
therapy (mean of 1.1/patient). Most patients reached a
minimum number of DUs within 3 months irrespective of
SSc. Nine subjects developed a total of 12 new DUs while
taking sildenaﬁl, of which one of the subjects was diagnosed
with calcinosis [15]. Based on this small, open label trial, it
seems that sildenaﬁl is well tolerated, and it could be a viable
optionforSSc-DUtherapy.Animportantcaveatofthisstudy
is the lack of uniformity in deﬁning SSc-DU (DUs due to
calcinosis tend to respond less to vasoactive therapies) and
the absence of a control group.
2.2. Vardenaﬁl. Vardenaﬁl is similar to sildenaﬁl in terms
of pharmacokinetic properties, with rapid onset of action,
maximal beneﬁt at 1 hour, and a half-life of about 4 hours.
It is the second PDE-5I to make its debut in the erectile
dysfunction arena at a dose of 10mg as needed.
Caglayan et al. published the results of an open-label
pilot study of vardenaﬁl (10mg twice daily for 2 weeks) in
patientswithRPin2006[16].Ofthe40subjectsrecruited,33
(82%)hadsecondaryRP.Allthevasoactivemedicationswere
discontinued at least one week prior to recruitment, and the
outcome measures included RCS, frequency, and duration of
RP attacks, and measures of peripheral blood ﬂow by laser
Doppler’s ﬂowmetry at room temperature and in the cold
exposure test room. Laser Doppler’s ﬂowmetry revealed that
70% (28) of the subjects had improved digital ﬂow, and, in
those individuals, the digital blood ﬂow measured at room
temperature increased by a mean of 21% and 30% at 1 hour
and 2 weeks compared to baseline at (P<0.01). The RCS
improved signiﬁcantly from baseline to the second week of
vardenaﬁl therapy (5.05 versus 3.54, P<0.001) [16]. As
far as we could ascertain this is the only published trial of
vardeniﬁl. Based on this information vardenaﬁl seems to be
well tolerated and shows RP improvement.
2.3. Tadalaﬁl. The longer half-life of this PDE-5I made
tadalaﬁl an attractive option as a daily dose for SSc-related
peripheralvasculopathy.Asmallopen-label studyof tadalaﬁl
(between 5 and 20mg every other day as needed) was
published in abstract format in 2005 [17]. Of the 15 patients
studied, 11 had SSc spectrum of diseases and the RCS was
reported to be 3.8 while on tadalaﬁl versus 6.9 without. Due
to the limited data available in the abstract, no meaningful
conclusions can be derived from this study.
A physiological study of tadalaﬁl in RP (mostly primary
RP, 18/20) was reported in 2007: this was a double-blind,
placebo-controlled cross-over study of 20 patients with RP
thatreceivedasingledoseof10mgoftadalaﬁlversusplacebo
[18]. The hypothesis that tadalaﬁl improves cold-induced
vasoconstriction was tested by measuring the digital blood
ﬂow with laser Doppler ﬂowmetry at rest and during two
graduated local heat and cold exposure cycles; skin blood
ﬂ o w( ﬂ u x )a n ds k i nt e m p e r a t u r ew e r er e c o r d e da tb a s e l i n e
and 90 minutes after receiving the drug. Tadalaﬁl did not
aﬀect the baseline ﬂux (P = 0.57) or skin temperature
(P = 0.69). Tadalaﬁl neither increased the maximal ﬂux
ﬂow during heating nor decreased the vasoconstriction
duringcooling,whichmightmeanthattadalaﬁlimprovesRP
through a diﬀerent mechanism [18].
There is evidence that tadalaﬁl improves peripheral
circulation in SSc-RP. A randomized controlled trial of
tadalaﬁl (20mg 2-3times/week) versus pentoxifylline for 4
weeks in men with severe RP associated with autoimmune
diseases was reported in abstract form in 2006 [19]. The
frequency (decline of 59% with tadalaﬁl versus 36% with
pentoxifylline) and duration of RP attacks and the RCS were
improved in the patients receiving tadalaﬁl. Also, physician
and patient assessments of RP improved at 4 weeks (P<
0.05 compared to 2 weeks, and P<0.05 versus controls).
Our interpretation of this study is limited as no speciﬁc
information is provided about the number of SSc patients
included in this study or about the statistical signiﬁcance
of some of the results. A more recent open-label study
of 20 male patients with SSc-RP receiving 10mg of daily
tadalaﬁl for 12 weeks was published in 2009. The primary
endpoint showed improvement in the RCS, the number of
RP attacks and a decrease in the plasma adrenomedullin and
endothelin-1 levels compared to baseline [20].
In 2009, Schiopu et al. reported a randomized, double-
blinded, placebo-controlled, crossover trial of tadalaﬁl at
aﬁ x e dd o s eo f2 0 m gd a i l yv e r s u sp l a c e b oi n3 9w o m e n
with SSc-RP [21]. The trial design prohibited use of any
other vasodilator therapies for RP, required a run-in period
to document presence of a minimum of 6 RP attacks per
week and excluded smokers. The treatment blocks were 4
w e e k se a c hw i t ha2 - w e e kw a s h o u ti nb e t w e e n .T h eo u t c o m e
measures included paper RP diary and RCS. There were not
suﬃcient DUs to permit an adequate statistical analysis of
the eﬀects on DUs. Although all measures showed overall
improvement, there was no signiﬁcant diﬀerence between
the change from baseline RCS, duration, and frequency of
attacksamongthetadalaﬁlandtheplacebogroups(RCS2.43
versus 2.53, frequency 2.08 versus 2.1, duration 40.61 versus
47.0) [21]. A year later, Shenoy et al. described the results
of a single-center, randomized, double-blind cross-over trial
of tadalaﬁl at 20mg on alternate days versus placebo in
subjects with SSc-RP which was conducted in India [22].
The trial design, although similar to the previous cross-
over trial of tadalaﬁl, included a longer treatment block (6
weeks) and a shorter washout (1 week), and allowed subjects
to continue all the previous RP-speciﬁc therapies. When
compared to the Schiopu et al. trial, the patients recruited
needed to have 4 RP attacks/week, as opposed to 6, and
the mean age of the 24 participants was younger (36.87
versus 52.9). The primary outcomes were similar: mean
change in RCS, duration, and frequency of RP attacks from
baseline. The secondary outcomes included assessment of
DUs, quality of life (QoL) measures, endothelial function,
and ﬂow-mediated dilatation of brachial artery. In this
study, the primary outcomes were signiﬁcantly better in the
tadalaﬁl group: frequency (2.29 versus 3.37, P<0.001),
duration (33.81 versus 54.89, P = 0.023), and RCS (3.86
versus 5.20, P<0.0005). All the 24 digital lesions healed4 International Journal of Rheumatology
during the tadalaﬁl treatment versus only 3 of the 13
DUs during the placebo treatment. The brachial artery
reactivity was measured using B-mode ultrasound imaging
and improved signiﬁcantly while subjects received active
drug (P<0.05). The levels of E-selectin and endothelin
1 were not signiﬁcantly diﬀerent between placebo and the
active treatment groups (P = 0.5 and 0.81, resp.) [22].
Following this above-mentioned single-center trial by
Shenoy et al, a multicenter randomized, double-blinded,
placebo-controlled study of tadalaﬁl at 20mg every other
d a yv e r s u sp l a c e b ow a sc o n d u c t e di n4c e n t e r sf r o mN o r t h
and Northeastern India and reported in an abstract form
[23]. Similar to Shenoy et al., the mean age of the recruited
subjects was lower than the mean age of the subjects in the
US tadalaﬁl trial (36.8 years in both Indian studies versus
52.9 years in the US study). This trial recruited 53 subjects,
and, after a 2 week run-in period, they were randomized
to tadalaﬁl 20mg every other day or placebo for the 8-
week treatment period. Similar to the Shenoy et al. trial,
improvement in RCS, duration, and frequency of RP attacks
was demonstrated (P<0.05, P<0.001, P<0.001, resp.),
along with signiﬁcant SSc-DU healing (14 out of 18 DUs
healed in the tadalaﬁl group compared to 5 out of 13 in
the placebo group) [23]. It is likely that the diﬀerences in
the trial design, speciﬁcally the concomitant RP therapies,
along with the lower average age (less disease severity and
more reversal changes, consistent with younger age) could
explain thediﬀerences in the results of these controlledtrials.
A signiﬁcant aspect on which all three studies seem to agree
was the excellent tolerability of the oral tadalaﬁl as a daily or
every other day therapy for SSc-RP.
2.4. Ongoing Clinical Trials. A phase IIa, randomized dou-
ble-blinded, placebo-controlled, cross-over trial to assess
the eﬃcacy of a novel, once daily PDE-5I (PF-00489791)
for the treatment of primary and SSc-related secondary
RP has just ﬁnished recruiting. This is a multicenter trial
sponsored by Pﬁzer (http://www.clinicaltrials.gov/ identiﬁer
NT01090492). Another phase II/III clinical trial is compar-
ing daily use of amlodipine (10mg) versus udenaﬁl daily
(100mg) in secondary RP in a double-blind, randomized,
cross-over design; aside from the RP common outcome
measures, the investigators are also assessing DUs and arte-
rial ﬂow velocity (http://www.clinicaltrials.gov/ identiﬁer:
NCT01280266).
The eﬀects of sildenaﬁl in SSc-RP as measured by the
microcirculator blood ﬂow, endothelial progenitor cells,
and serum levels of vascular endothelium growth factor is
ongoing (http://www.clinicaltrials.gov/ identiﬁer: NCT013-
47008). A multicenter double-blinded, placebo-controlled
trial is also currently randomizing participants to either
sildenaﬁl (20mg three times a day) or placebo for 90 days
to assess healing of SSc-DUs (http://www.clinicaltrials.gov/
identiﬁer: NCT01295736).
3. Conclusions
The SSc-related vasculopathy (including RP and DUs) lacks
FDA-approved therapies. The class of PDE-5Is is a well-
tolerated vasoactive therapy for patients with SSc-related
vasculopathy. After a surge of clinical case reports, case
series and open-label studies published in the mid 2000s,
large, multicenter, controlled trials of PDE-5Is in SSc-related
vasculopathy remain underdeveloped. Most of the published
clinical trials in SSc-RP focus on sildenaﬁl and tadalaﬁl
although the one study reported with vardenaﬁl has shown
it to be well tolerated with a beneﬁcial impact on RP.
Currently, the available evidence for the eﬃcacy of PDE-
5I’s for SSc RP/DUs is thin. Deﬁnite conclusions are hard to
reach as studies have shown conﬂicting results. Comparisons
are diﬃcult as patient populations and outcome measures
a r en o tu n i f o r m .T h e r ea r ee ﬀorts to address the questions
of placebo response in RP by designing trials focused
on objective vascular markers, QoL, and physicians’ and
patients’ global assessments. Robust clinical evidence that
PDE-5Is, alone or in conjunction with traditional vasoactive
therapy, improve SSc-RP and heal SSc-DUs is still lacking.
Clinical trials involving selective PDE-5Is are ongoing.
The great clinical need for a tolerable, aﬀordable thera-
peutic option for SSc-RP and SSc-DU remains. The clinical
research community recognizes PDE-5Is as an excellent
potential option for SSc-related vasculopathy.
References
[1] C. S. Lin, G. Lin, Z. C. Xin, and T. F. Lue, “Expression,
distribution and regulation of phosphodiesterase 5,” Current
Pharmaceutical Design, vol. 12, no. 27, pp. 3439–3457, 2006.
[ 2 ]R .M .W a l l i s ,J .D .C o r b i n ,S .H .F r a n c i s ,a n dP .E l l i s ,“ T i s s u e
distribution of phosphodiesterase families and the eﬀects of
sildenaﬁl on tissue cyclic nucleotides, platelet function, and
thecontractileresponsesoftrabeculaecarneaeandaorticrings
in vitro,” The American Journal of Cardiology,v o l .4 ,p p .3 C –
12C, 1999.
[3] B. Zhu, L. Zhang, M. Alexeyev, D. F. Alvarez, S. J. Strada, and
T. Stevens, “Type 5 phosphodiesterase expression is a critical
determinant of the endothelial cell angiogenic phenotype,”
American Journal of Physiology—Lung Cellular and Molecular
Physiology, vol. 296, no. 2, pp. L220–L228, 2009.
[4] P.J.Wright,“Comparisonofphosphodiesterasetype5(PDE5)
inhibitors,” International Journal of Clinical Practice, vol. 60,
no. 8, pp. 967–975, 2006.
[5] N. Gali` e, H. A. Ghofrani, A. Torbicki et al., “Sildenaﬁl
citrate therapy for pulmonary arterial hypertension,” The New
England Journal of Medicine, vol. 353, no. 20, pp. 2148–2157,
2005.
[6] N. Gali` e, B. H. Brundage, H. A. Ghofrani et al., “Tadalaﬁl
therapyforpulmonaryarterialhypertension,” Circulation,vol.
119, no. 22, pp. 2894–2903, 2009.
[7] Z. Jing, Z. Yu, J. Shen et al., “Vardenaﬁl in pulmonary
arterial hypertension: a randomized, double-blind, placebo-
controlled study,” American Journal of Respiratory and Critical
Care Medicine , vol. 183, no. 12, pp. 1723–1729, 2011.
[8] F. Wigley, “Clinical practice. Raynaud’s Phenomenon,” The
New England Journal of Medicine, vol. 347, pp. 1001–1008,
2002.
[9] E. Schiopu, A. J. Impens, and K. Phillips, “Digital ischemia
in scleroderma spectrum of diseases,” International Journal of
Rheumatology, vol. 2010, Article ID 923743, 8 pages, 2010.International Journal of Rheumatology 5
[10] G. Jackson, “Vardenaﬁl—PDE5 inhibitor number 3,” Interna-
tional Journal of Clinical Practice, vol. 58, no. 3, p. 229, 2004.
[11] J. Gore and R. Silver, “Oral sildenaﬁl for the treatment
of Raynaud’s phenomenon and digital ulcers secondary to
systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 64,
no. 9, p. 1387, 2005.
[12] N. Kumar, B. Griﬃths, and J. Allen, “Thermographic and
symptomatic eﬀect of a single dose of sildenaﬁl citrate on
Raynaud’s phenomenon in patients with systemic sclerosis: a
potential treatment,” The Journal of Rheumatology, vol. 33, no.
9, pp. 1918–1919, 2006.
[13] H. Watanabe, S. Nishio, E. Ohmae et al., “Sildenaﬁl improves
forearm blood ﬂow in patients with Raynauds phenomenon,”
The European Heart Journal, vol. 25 (supplement), p. 202,
2004.
[14] R. Fries, K. Shariat, H. von Wilmowsky, and M. B¨ ohm, “Silde-
naﬁl in the treatment of Raynaud’s phenomenon resistant to
vasodilatory therapy,” Circulation, vol. 112, no. 19, pp. 2980–
2985, 2005.
[15] C. S. Brueckner, M. O. Becker, T. Kroencke et al., “Eﬀect of
sildenaﬁl on digital ulcers in systemic sclerosis: analysis from
a single centre pilot study,” Annals of the Rheumatic Diseases,
vol. 69, no. 8, pp. 1475–1478, 2010.
[16] E. Caglayan, M. Huntgeburth, T. Karasch et al., “Phospho-
diesterase type 5 inhibition is a novel therapeutic option in
Raynaud disease,” Archives of Internal Medicine, vol. 166, no.
2, pp. 231–233, 2006.
[17] S. Baak, “Treatment of Raynaud’s phenomena with the PDE-
5 inhibitor, Cialis (tadalaﬁl) in patients with scleroderma and
lupus,” Arthritis and Rheumatism, vol. 52, p. S169, 2005.
[ 1 8 ]E .A .F r i e d m a n ,P .A .H a r r i s ,A .J .W o o d ,C .M .S t e i n ,a n dD .
Kurnik,“Theeﬀectsoftadalaﬁloncold-inducedvasoconstric-
tion in patients with Raynaud’s phenomenon,” Clinical Phar-
macology & Therapeutics, vol. 81, no. 4, pp. 503–509, 2007.
[19] G. Carlino, “Treatment of Raynaud’s phenomenon with
tadalaﬁl, a phosphodiesterase-5 inhibitor (abstract),” Annals
of the Rheumatic Diseases, vol. 64, p. 258, 2005.
[20] E. Rosato, C. Letizia, M. Proietti et al., “Plasma adrenome-
dullinandendothelin-1levelsarereducedandRaynaud’sphe-
nomenon improved by daily tadalaﬁl administration in male
patients with systemic sclerosis,” Journal of Biological Regula-
tors and Homeostatic Agents, vol. 23, no. 1, pp. 23–29, 2009.
[21] E. Schiopu, V. M. Hsu, A. J. Impens et al., “Randomized
placebo-controlled crossover trial of tadalaﬁl in Raynaud’s
phenomenon secondary to systemic sclerosis,” The Journal of
Rheumatology, vol. 36, no. 10, pp. 2264–2268, 2009.
[ 2 2 ]P .D .S h e n o y ,S .K u m a r ,L .K .J h ae ta l . ,“ E ﬃcacy of tada-
laﬁl in secondary Raynaud’s phenomenon resistant to vaso-
dilator therapy: a double-blind randomized cross-over trial,”
Rheumatology, vol. 49, no. 12, pp. 2420–2428, 2010.
[23] V. Agarwal, P. Ghosh, A. Sharma et al., “Eﬃcacy of Tadalaﬁl
in Raynaud’s phenomenon secondary to systemic sclerosis: a
double blind randomized placebo controlled parallel group
multicenter study,” Arthritis and Rheumatism, vol. 62 (supple-
ment), p. S872, 2010.